Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
Year: 2025
Type: article
Study design: Clinical Trial
Source: Cancer Discovery
Authors: Qin Xu, Zhengrong Deng, Jing Liu, Yanhong Zhuo, Fei Zhu, Lele Chang, Qin Liu, Yajuan Fu, Peiwei Li, Yunyun Liu, Songhua Huang, Li Li, Xingyun Xie, Ying Chen, Yingtao Lin, Lele Zang, Meifang Ke, Li Chen, Xiaoxia Huang, Cong Wang, Yanhong Wang, Yaxin Kang, Yuqin Wang, Mingxuan Zhu, Huiqi Zhang, Zhixin Wang, Peidong Zhang, Dan Hu, Huaiwu Lu, Yang Sun, Shengtao Zhou
Institutions: Fujian Medical University, Fujian Provincial Cancer Hospital, Sichuan University, West China Second University Hospital of Sichuan University, State Key Laboratory of Biotherapy, University of Hong Kong, Fujian Normal University, Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Shandong Tumor Hospital, Shandong Provincial Hospital, Shandong First Medical University, Second Affiliated Hospital of Fujian Medical University, West China Hospital of Sichuan University
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4416711754